Solaray Ashwagandha 470 mg Review

It means something, but less than buyers usually assume. Solaray was founded in 1973, which makes the company older than most ashwagandha buyers — that's a real track record signal. Across 50+ years they've built distribution into Sprouts, Whole Foods, Vitamin Shoppe, and most independent health stores; you can find Solaray on a shelf in nearly every American city. Their internal QC discipline is competent and consistent across decades. But brand longevity is QC reputation, not active density — Solaray has never licensed KSM-66 or Sensoril, declares only a 1.5% withanolide extract (7 mg/cap) on the label, and has never been the subject of a published placebo-controlled RCT for testosterone. The reputation buys you 'this bottle won't contain contaminants or wildly wrong dose'; it doesn't buy you 'the actives match the trial-evidence base.'

Brand strategy. Solaray's positioning is 'legacy US supplement brand with broad product line' (they sell 1000+ SKUs across vitamins, minerals, herbs, blends). The KSM-66 / Sensoril licensing model adds cost that breaks the value-tier across that many SKUs — Solaray would rather sell a generic, low-standardisation ashwagandha extract at $15 than a patent-licensed 5% extract at $22. The trade-off is consistent across their entire herb line: they bet on brand-trust + broad distribution + price stability rather than per-SKU patent-tier standardisation. This is a coherent strategy at the legacy retail tier; it's just not the right strategy for the testosterone-trial endpoint.

NOW Foods wins on active density; both disclose. They are legacy household brands with strong QC reputations and broad offline distribution, and both print their withanolides on the label: NOW's 450 mg cap at 2.5% delivers a declared ~11 mg withanolides; Solaray's 470 mg cap declares 7 mg (1.5%). (Corrected 27 Aug 2026: we originally wrote that Solaray published no percentage — the panel states it plainly.) Both run in-house QC labs; Solaray's label carries a 'Lab Verified' seal (NOW's certification tier isn't confirmed here from the label alone). For the same price tier, NOW gives you ~57% more declared actives per cap at a lower price, which is why it ranks ahead; Solaray's case is the 50-year brand and its retail ubiquity.

For some buyers, yes. If your priority order is: (1) brand I've heard of, (2) available at the health food store I already shop at, (3) price under $20/month, (4) trust the company won't ship contaminated product — Solaray clears all four bars cleanly. The 50-year track record IS meaningful for downside risk (no major recalls, no major QC scandals, no major regulatory actions). What it doesn't clear: the testosterone-trial active-load math. If your priority order includes (5) actives match published trial concentration, Solaray fails on that single criterion because the disclosed concentration (1.5%, 7 mg/cap) is below trial-active doses. Brand trust + offline availability is a real reason to buy this bottle; testosterone-trial evidence anchoring is not.

Exactly 7 mg per capsule — the Supplement Facts panel declares '470 mg (Supplying 7 mg [1.5%] Withanolides)'. (We originally wrote that no percentage was declared and estimated 4-9 mg; the label states it plainly — corrected 27 Aug 2026, and 7 mg sits inside our old estimate.) That is below the low-dose arm of Salve 2019 (~12.5 mg withanolides at 250 mg KSM-66) and well below the Wankhede 2015 testosterone dose (30 mg at 600 mg KSM-66). At 1 cap/day you're under-dosed for testosterone; at 2 caps/day ($30/month effective) you reach ~14 mg — just past the stress-trial load — but the per-mg cost climbs well above patent-extract competitors.

Honestly, rarely. Nutricost is $14/month (Solaray is $15) for the real KSM-66 patent + verified 5% withanolide standardisation + Ixoreal-licensed extract at the trial-exact 600 mg dose. The only reasons to pick Solaray over Nutricost: (1) you need offline availability and can't wait for Amazon shipping (Solaray is at every health food store; Nutricost is Amazon-only). (2) You have an established brand preference for Solaray across your supplement stack. (3) You distrust generic-brand budget options philosophically. For all three, Solaray is the right pick despite the standardisation gap. For everyone else, Nutricost wins the comparison cleanly.

Modest probability of mild effect. At 1 cap/day = a declared 7 mg withanolides, you're below most clinical-trial active doses for testosterone. Some cortisol effect is plausible, which could nudge T downstream — but the effect should be smaller than KSM-66 protocols at the same gram weight. At 2 caps/day = 14 mg, you're approaching but not matching trial-active-dose territory. Honest framing: this bottle is more likely to deliver placebo-comparable results for testosterone than KSM-66 brands at this dose level, because the declared 1.5% standardisation sits well below the 5% trial extracts. Cortisol/sleep effects more likely than testosterone effects.

1. [1] Wankhede 2015 PMID 26609282 — Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. 600 mg/day KSM-66 (= 30 mg withanolides) for 8 weeks in resistance-trained men measured serum testosterone +96 ng/dL. Cited as the active-load benchmark — Solaray's declared 7 mg withanolides at 1 cap/day is well below this trial dose.
2. [2] Lopresti 2019 (testosterone) PMID 30854916 — A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males. 57 overweight men aged 40-70 took Shoden (21 mg withanolide glycosides a day) or placebo for 8 weeks each in a crossover trial. Testosterone rose 14.7% and DHEA-S 18% more than on placebo; cortisol, fatigue and sexual well-being did not differ. The extract was Shoden, not KSM-66.
3. [3] Chandrasekhar 2012 PMID 23439798 — A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. 600 mg/day KSM-66 for 60 days in chronically stressed adults reduced perceived stress -44% and morning cortisol -27.9%. Patent-extract benchmark — Solaray's preparation has no parallel published RCT.
4. [4] Lopresti 2019 (stress) PMID 31517876 — An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. 60 stressed adults took 240 mg of Shoden or placebo once daily for 60 days. Anxiety scores (HAM-A) fell more than on placebo, as did morning cortisol and DHEA-S. Sleep was not an outcome. The extract was Shoden, not KSM-66.
5. [5] Salve 2019 PMID 32021735 — Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. 60 stressed adults took 250 or 600 mg a day of ashwagandha root extract, or a placebo, for 8 weeks. Perceived stress and serum cortisol fell at both doses. Sleep quality improved compared with placebo. It used a high-concentration root extract, which Solaray's low-standardisation (1.5%) extract does not directly match.
6. [6] Auddy 2008 — A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: a double-blind, randomized, placebo-controlled study. 125-250 mg/day Sensoril (10% withanolides) reduced cortisol -24.2%. Demonstrates the role of standardised concentration in predictable dose-response — Solaray's 1.5% extract sits far below Sensoril's 10% concentration.